Higher levels of vitamin D-binding protein at the time of delivery, but not during the middle of pregnancy, were associated with a lower risk for type 1 diabetes.
Providers should maximize women’s health during the interpregnancy period, continuing care beyond the immediate postpartum period.
Postpartum women with an elevated BMI score and a history of hypertensive disorders during pregnancy have an increased risk of developing type 2 diabetes.
Large for gestational age (LGA) is a stronger marker than maternal diabetes for subsequently being overweight or obese in early childhood.
There is a slight association between maternal gestational weight gain and offspring bone mineralization in under/normal weight women, but not in overweight/obese women.
Pregnant women with T1D who received MDI therapy had a larger decrease in HbA1c levels and were less likely to report gestational hypertension, neonatal hypoglycemia, and NICU admissions than women who used insulin pump therapy during pregnancy.
Paying a surrogate to carry a fetus shoehorns a fourth, and fifth, party into the already tight therapeutic triangle formed by the biological mom, fetus, and physician.
Current trial evidence does not support the treatment of subclinical hypothyroidism diagnosed in pregnancy.
Compared to standard insulin treatment, noninsulin antidiabetic agents did not present an increased risk for fetal losses or major malformations when used in the first trimester of pregnancy.
Results suggest that first trimester use of insulin analogues does not increase the risk for a congenital anomaly in women with diabetes compared with the use of human insulin.
